Abbott has received FDA approval for its Liberta RC DBS (rechargeable deep brain stimulation) system, marking a significant advancement in the treatment of movement disorders. The device stands out as the most efficient among FDA-approved DBS systems, requiring only 10 recharge sessions annually for most users. Its compact size, approximately 31% smaller than other commonly used rechargeable DBS devices in the U.S., adds to its appeal.

The Liberta RC DBS system introduces remote programming capabilities, a key feature for patients seeking convenience and enhanced communication with healthcare professionals. This innovative technology is made possible through compatibility with Abbott’s proprietary NeuroSphere virtual clinic. Patients can now interact with doctors, ensure proper device settings, and receive new treatment settings remotely.

One of the notable advantages of the Liberta RC DBS is its minimal recharge frequency, allowing users the flexibility to lead active lives. Under standard settings, the device requires recharging every 37 days, or 10 times a year, using a wireless charger. Even for users on a weekly charging schedule, a mere 30 minutes of charging is sufficient. The wireless system enables users to stay active while wearing the device, and it can be fully recharged twice before needing to be plugged in again.

Dr. Paul Larson, a professor of neurosurgery at the University of Arizona, emphasizes the significance of the Liberta RC DBS, stating that patients often choose rechargeable DBS systems for their compact size. Still, the tradeoff has traditionally been recharge frequency affecting their lifestyle. The Liberta RC DBS excels in both areas, offering a compact rechargeable device with the lowest recharge requirement among FDA-approved DBS systems.

Article written by Bert SEAN WHOOLEY



Mass Device